Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 2, 2002, Pages 559-566

  Haddad, John J ^a   Land, Stephen C ^b   Tarnow Mordi, William O ^c   Zembala, Marek ^d   Kowalczyk, Danuta ^d   Lauterbach, Ryszard ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; 4 [[3',4' (METHYLENEDIOXY)BENZYL]AMINO] 6 METHOXYQUINAZOLINE; AMRINONE; CYCLIC AMP; CYCLIC GMP; CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CYTOKINE PRODUCTION; DRUG INHIBITION; ENZYME INHIBITION; ENZYME REGULATION; IMMUNOPHARMACOLOGY; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY EPITHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; INTERLEUKIN-6; ISOENZYMES; LIPOPOLYSACCHARIDES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PULMONARY ALVEOLI; RATS; RESPIRATORY SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036154530     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.2.559     Document Type: Article

References (80)

1. Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms
2. SB-207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
3. Diminished response of Werner's syndrome fibroblasts to growth factors PDGF and FGF
4. Cachectin: More than a tumor necrosis factor
5. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine
6. A family of human phosphodiesterases homologues to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs
7. Modulation of inflammation and immunity by cyclic AMP
8. 4 in a novel human whole blood assay
9. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome
10. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery
11. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis
12. Cyclic GMP phosphodiesterase-5: Target of sildenafil
13. Pharmacological modulation of secondary mediator systems-cyclic AMP and cyclic GMP-on inflammatory hyperalgesia
14. Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3)
15. Cyclic nucleotide phosphodiesterase inhibitors
16. Mechanisms of airway inflammation in cystic fibrosis
17. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation
18. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats
19. Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves anti-tumor efficacy
20. Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation
21. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein
22. Over-expression of transforming growth factor a in psoriatic epidermis
23. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
24. Anti-TNF-α of rheumatoid arthritis: What have we learned?
25. Oxidant injury to the alveolar epithelium: Biochemical and pharmacologic studies
26. A novel dual regulator of tumor necrosis factor-α and interleukin-10 protects mice from endotoxin-induced shock
27. Organization and regulation of mitogen-activated protein kinase signaling pathways
28. Pentoxifylline ameliorates cerulein-induced pancreatitis in rats: Role of glutathione and nitric oxide
29. SB-207499 (Ariflo), a second-generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor a and interleukin-4 production in vivo
30. VX-745 Vertex Pharmaceuticals
31. 2-evoked regulation of HIF-1 α and NF-κ B in perinatal lung epithelium requires glutathione biosynthesis
32. The differential expression of apoptosis factors in the alveolar epithelium is redox sensitive and requires NF-κB (RelA)-selective targeting
33. 193-195 receptor antagonism in the alveolar epithelium
34. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity Evidence for inhibition by glutathione oxidation in alveolar epithelial cells
35. 2/ROS) dependent release of IL-1β, IL-6 and TNF-α: Evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium
36. Thiol regulation of pro-inflammatory cytokines reveals a novel immunopharmacological potential of glutathione in the alveolar epithelium
37. The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-κB targeting in the alveolar epithelium
38. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent
39. Inosine inhibits inflammatory cytokine production by a post-transcriptional mechanism and protects against endotoxin-induced shock
40. A novel anti-rheumatic drug suppresses tumor necrosis factor-α and augments interleukin-10 in adjuvant arthritic rats
41. Tailoring cAMP-signalling responses through isoform multiplicity
42. Regulation of IL-15-stimulated TNF-α production by rolipram
43. Cytokines of the lung
44. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells
45. Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits
46. Effect of pentoxifylline on nitric oxide released by murine macrophages
47. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial
48. Pentoxifylline reduces plasma tumor necrosis factor-α concentration in premature infants with sepsis
49. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia
50. Guanylyl cyclases and signaling by cyclic GMP
51. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
52. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages
53. Alveolar epithelial barrier: Role in lung fluid balance in clinical lung injury
54. Targeting the alveolar epithelium in acute lung injury: Keratinocyte growth factor and regulation of the alveolar epithelial barrier
55. Cytokines: Overview
56. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function
57. Chemotherapeutic potential of phosphodiesterase inhibitors
58. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
59. Resistance of the alveolar epithelium to injury from septic shock in sheep
60. The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications
61. Amrinone reduces ischaemia-reperfusion injury in rat heart
62. Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis
63. New ideas on the pathophysiology and treatment of lung disease
64. Bronchopulmonary dysplasia and oxidative stress: Are we closer to an understanding of the pathogenesis of BPD?
65. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
66. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects
67. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock
68. Mitogen-activated protein kinase cascades and regulation of gene expression
69. Serum concentrations of pentoxifylline and its metabolites in premature infants with sepsis when administered by continuous intravenous infusion
70. Immunological functions of the pulmonary epithelium
71. 2: Implications for the therapeutic use of β-adrenoreceptor agonists
72. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types 3 and 4
73. Anti-asthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB-207499 (Ariflo) in the Guinea pig
74. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-α, IL-1β and IL-10 by human leukocytes
75. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro
76. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
77. Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment
78. Methyxanthine inhibitors of phosphodiesterases
79. Genes, receptors, signals and responses to lipopolysaccharide endotoxin
80. Pathogenesis of respiratory infections and host defenses